Review: Protein misfolding in neurodegenerative diseases
Peer-reviewed publication on new strategies to target misfolded protein aggregates at various steps of protein production and processing…
A hallmark of neurodegenerative proteinopathies is the formation of misfolded protein aggregates, so therapeutic options are currently being explored to target different steps in the production and processing of proteins implicated in neurodegenerative disease. However, there are major challenges that impact the development of novel therapies, including incomplete knowledge of disease targets and a lack of biomarkers to monitor disease progression and therapeutic response.
This review paper is partly based on presentations at “Protein Misfolding—Implications and Strategies,” an open scientific satellite symposium held in conjunction with the Society for Neuroscience’s 45th Annual Meeting in 2015, sponsored and organized by Charles River.
The rest of this review is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Related content from this organisation
- Charles River Laboratories announces extended relationship with The Michael J. Fox Foundation
- Charles River Laboratories expands services for early discovery screening
- Biomarker endpoints for Parkinson’s disease
- in vitro phenotypic assays for Parkinson’s disease
- Charles River Laboratories announces new tumour model compendium